Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background and Aims: Anti‐tuberculosis drugs remain as an important cause of drug‐induced liver injury (DILI) worldwide. Adverse drug reactions reduce the effectiveness of treatment. We aimed to determine the incidence and risk factors associated with anti‐tuberculosis DILI (ATDILI). Methods: Using established criteria and causality assessment methods, risk factors for ATDILI were identified in a contemporary cohort and validated in another cohort prospectively. Independent determinants of ATDILI were identified using Cox regression analysis. Results: In the derivation cohort (n = 3155), 170 (5.4%) developed ATDILI of which 27 (15.9%) developed jaundice; 9(5.3%) developed acute liver failure (ALF) and 3 died. Among HBsAg positive patients, 11/27 (40.7%) of ATDILI developed after 3 months of starting treatment. In addition, of 218 (6.9%) who developed raised alanine transferase (ALT) levels ≥3 times upper limit normal, 193 (88.5%) resolved and 25 (11.4%) progressed to DILI. Age (HR = 1.014, 95% CI: 1.005‐1.023), baseline ALT (HR = 1.014, 95% CI: 1.003‐1.024), haemoglobin (HR = 1.011, 95% CI: 1.002‐1.020) and HBsAg positivity (HR = 1.516, 95% CI: 1.004‐2.290) were independent risk factors for DILI. In the second cohort (n = 1497) of which 85 (5.7%) developed ATDILI. Age (HR = 1.029, 95% CI: 1.003‐1.056), baseline AST (HR = 1.036, 95% CI: 1.010‐1.062), previous TB treatment (HR = 3.894, 95% CI: 1.304‐11.625) and active drinking (HR = 3.624, 95% CI: 1.147‐11.454) were risk factors for developing jaundice. Conclusion: Elevation of ALT of ≥3 × ULN during anti‐TB treatment resolves in the vast majority without developing serious consequences. In two cohorts involving 4652 patients, incidence of ALF and death because of ATDILI are low. Age, baseline ALT, haemoglobin and HBsAg positivity are risk factors for the development of DILI and these inform monitoring and management of these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the incidence of severe DILI appears to be lower than previously appreciated,180 isoniazid continues to be a leading cause of DILI‐related ALF in the United States and worldwide (Table 2).181–184”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P. B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.002 · Cited by 615
Self-citationSattar, N., McConnachie, A., Ford, I., Gaw, A., Cleland, S. J., Forouhi, N. G., McFarlane, P., Shepherd, J., Cobbe, S., & Packard, C. (2007) · Diabetes · doi:10.2337/db06-1256 · Cited by 127
Research works printed but not linked: 29
- WHO, 2019, Global tuberculosis report 2019
- 10.1186/1471-2458-10-267 · DOI
- 10.1016/S0140-6736(04)16764-0 · DOI
- 10.1016/S0140-6736(04)17141-9 · DOI · Paper page
- 10.1007/s00228-012-1429-9 · DOI · Paper page
- 10.1002/hep.510310129 · DOI · Paper page
- 10.1086/598929 · DOI · Paper page
- 10.1186/1471-2458-4-68 · DOI · Paper page
- 10.1002/hep.23534 · DOI · Paper page
- 10.1002/hep.23805 · DOI
- 10.1186/s12916-018-1033-7 · DOI · Paper page
- 10.1164/rccm.201105-0850OC · DOI · Paper page
- 10.1186/s12879-017-2330-z · DOI · Paper page
- 10.1016/j.jceh.2012.12.001 · DOI · Paper page
- World Health Organization, 2009, Treatment of Tuberculosis: Guidelines for National Programmes
- 10.1016/0895-4356(93)90102-7 · DOI · Paper page
- 10.1038/clpt.2011.58 · DOI · Paper page
- 10.1016/S0016-5085(19)32568-5 · DOI · Paper page
- 10.1111/liv.12988 · DOI · Paper page
- 10.1002/hep.29283 · DOI · Paper page
- 10.1111/j.1440-1746.2012.07279.x · DOI · Paper page
- 10.1136/thx.51.2.132 · DOI · Paper page
- Singla R, 2010, Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity, Indian J Med Res, 132, 81
- 10.1136/bmj.38050.593634.63 · DOI · Paper page
- 10.1016/j.cgh.2018.12.013 · DOI · Paper page
- 10.1016/j.ajpath.2011.03.029 · DOI
- 10.1086/313809 · DOI · Paper page
- 10.5604/01.3001.0012.0920 · DOI
- 10.1016/j.jhep.2011.05.027 · DOI
Cited by
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
“[179] Although the incidence of severe DILI appears to be lower than previously appreciated,[180] isoniazid continues to be a leading cause of DILI‐related ALF in the United States and worldwide (Table 2).”
Background
Metadata
- Authors
- Jiang, F., Yan, H., Liang, L., Du, J., Jin, S., Yang, S., Wang, H., Hu, T., Zhu, Y., Wang, G., Hu, Y., Cai, T., & Aithal, G. P.
- Affiliations
- Department of Pharmacy Hwamei Hospital University of Chinese Academy of Sciences Ningbo Institute of Life and Health Industry Ningbo China
- Department of Infectious Diseases Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province Hwamei Hospital University of Chinese Academy of Sciences Ningbo Institute of Life and Health Industry Ningbo China
- Department of Infectious Diseases Wenling Hospital University of Wenzhou School of Medicine Taizhou China
- NIHR Nottingham Biomedical Research Centre Nottingham University Hospitals NHS Trust and University of Nottingham Nottingham UK
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2021-05-03
- Volume
- 41
- Issue
- 7
- Pages
- 1565-1575
- ISSN
- 1478-3223
- 1478-3231
- Cited by
- 79
- References
- 5
- Language
- en
- Funders
- Natural Science Foundation of Zhejiang Province (LGF20H030006)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. https://app.cochat.ai/papers/10.1111/liv.14896
- The paper
- Jiang, F., Yan, H., Liang, L., Du, J., Jin, S., Yang, S., Wang, H., Hu, T., Zhu, Y., Wang, G., Hu, Y., Cai, T., & Aithal, G. P. (2021). Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. Liver International. https://doi.org/10.1111/liv.14896
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.